| Dalrymple Bay Infrastructure Limited (DBI) FULLY PAID ORDINARY/NOTES STAPLED SECURITIES |
Industrials |
$2,018 |
2024 Half Year Financial Results
|
26 Aug 2024 8:50AM |
$3.060 |
$4.070 |
risen by
33.01%
|
|
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$384 |
FY24 Kogan.com Appendix 4E&Preliminary Financial Statements
|
26 Aug 2024 8:50AM |
$4.340 |
$3.870 |
fallen by
10.83%
|
|
KGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for FY24 was $844.8 million, a decrease from $1,429.6 million in FY23.
- Gross profit for FY24 was $187.4 million, down from $307.4 million in FY23.
- Net loss after tax for FY24 was $25.9 million, compared to a profit of $11.3 million in FY23.
- Decrease in active customers to 3.33 million as at 30 June 2024, down from 3.97 million as at 30 June 2023.
- Kogan.com declared fully franked dividends totaling 6.0 cents per share in FY24.
- Introduction of new customer loyalty program 'Kogan First Loyalty' with 400,000 subscribers.
- Significant reduction in inventory to $79.4 million as at 30 June 2024, compared to $161.1 million as at 30 June 2023.
- Focus on improving operational efficiencies and reducing costs throughout FY24.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Elsight Limited (ELS) ORDINARY FULLY PAID |
Information Technology |
$159 |
Appendix 4D & Half Year Financial Report
|
26 Aug 2024 8:49AM |
$0.310 |
$0.875 |
risen by
182.26%
|
|
ELS - Price-sensitive ASX Announcement
Full Release
Key Points
- Elsight Limited's revenue increased by 83% in H1 2024 compared to H1 2023.
- Significant new customers include Lockheed Martin and ACSL.
- Recurring revenue increased by 108% from H1 2023 to H1 2024.
- Net loss decreased to $1,706,836 from $1,941,598 in H1 2023.
- Cash and cash equivalents decreased from $2,702,593 at the end of 2023 to $1,968,383 at the end of June 2024.
- The company plans to expand its team due to increased government tenders and RFPs in the defence sector.
- No dividends were paid, recommended, or declared during the reporting period.
- The burn rate decreased by 43% from H1 2023 to H1 2024.
- Elsight's new focus on defence industries resulted in higher sales and market penetration.
- Convertible notes payable amounted to $5,384,999 as of June 30, 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GenusPlus Group Ltd (GNP) ORDINARY FULLY PAID |
Industrials |
$609 |
Dividend/Distribution - GNP
|
26 Aug 2024 8:49AM |
$2.280 |
$3.380 |
risen by
48.25%
|
|
| Infomedia Limited (IFM) ORDINARY FULLY PAID |
Information Technology |
$462 |
Dividend/Distribution - IFM
|
26 Aug 2024 8:49AM |
$1.765 |
$1.220 |
fallen by
30.88%
|
|
| IVE Group Limited (IGL) ORDINARY FULLY PAID |
Communication Services |
$401 |
Updated Securities Dealing Policy
|
26 Aug 2024 8:48AM |
$2.140 |
$2.590 |
risen by
21.03%
|
|
| Aldoro Resources Ltd (ARN) ORDINARY FULLY PAID |
Materials |
$57 |
Corporate Update & Board Transition
|
26 Aug 2024 8:48AM |
$0.075 |
$0.320 |
risen by
326.67%
|
|
| Energy Resources of Australia Limited (ERA) ORDINARY FULLY PAID 'A' |
Energy |
$1,013 |
Business Update Presentation
|
26 Aug 2024 8:48AM |
$0.016 |
$0.003 |
fallen by
83.87%
|
|
ERA - Price-sensitive ASX Announcement
Full Release
Key Points
- ERA is seeking judicial review of the refusal to renew the Jabiluka Mineral Lease.
- ERA's primary focus is the rehabilitation of the Ranger Project Area.
- Without an equity raise, ERA will likely breach its minimum cash reserve of $50m by Q4 2024 and deplete its cash resources by early 2025.
- ERA plans to conduct investor soundings to determine interest in an equity raise to fund rehabilitation activities.
- ERA appointed Rio Tinto to manage the Ranger Rehabilitation Project under a new Management Services Agreement.
- ERA applied for an extension to its section 41 Authority to extend its existing Ranger authority beyond January 2026.
- ERA aims to raise at least $210m through an equity raise to meet its rehabilitation requirements.
- The total rehabilitation expenditure expected from 1 July 2024 to the end of 2027 is estimated at $986m.
- ERA's liquidity position as of 30 June 2024 includes $128m in available cash and $126m in bank guarantees.
- The Ranger Rehabilitation Trust Fund holds $522m, but drawdown requires Commonwealth Government approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dalrymple Bay Infrastructure Limited (DBI) FULLY PAID ORDINARY/NOTES STAPLED SECURITIES |
Industrials |
$2,018 |
Appendix 4D and Half Year Financial Report
|
26 Aug 2024 8:47AM |
$3.060 |
$4.070 |
risen by
33.01%
|
|
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$33 |
Investor Presentation 30 June 2024 Results
|
26 Aug 2024 8:46AM |
$0.230 |
$0.115 |
fallen by
50%
|
|
EYE - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 group sales of A$23.3 million, a 35% increase compared to the previous corresponding period.
- Sales in the USA surged by 71%, reaching US$11.4 million (A$17.3 million).
- Group EBITDA loss improved by 33% (A$2.9 million) from FY23.
- The glaucoma segment showed significant improvement with a 54% increase in EBITDA (A$3.3 million improvement).
- The iTrack Advance device is redefining early-stage glaucoma treatment.
- Substantial growth in the global glaucoma surgical device market projected, with a focus on canaloplasty as a viable alternative to traditional medication.
- Proposed 30% increase in reimbursement rates for canaloplasty by CMS, effective from January 2025.
- Expansion of the USA sales team and increased productivity expected to drive further sales growth.
- Significant investment in sales and marketing to support product and brand awareness.
- Positive outlook for future profitability driven by improved gross margins and operating expenditure management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EVT Limited (EVT) ORDINARY FULLY PAID |
Communication Services |
$2,641 |
Dividend/Distribution - EVT
|
26 Aug 2024 8:46AM |
$11.030 |
$16.250 |
risen by
47.33%
|
|
| Infomedia Limited (IFM) ORDINARY FULLY PAID |
Information Technology |
$462 |
Appendix 4G & Corporate Governance Statement
|
26 Aug 2024 8:46AM |
$1.765 |
$1.220 |
fallen by
30.88%
|
|
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$33 |
Full Year Financial Results
|
26 Aug 2024 8:46AM |
$0.230 |
$0.115 |
fallen by
50%
|
|
EYE - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 group sales A$23.3 million, up 35% compared to the prior corresponding period in constant currency.
- Sales in the USA surged by 71%, reaching US$11.4 million (A$17.3 million).
- Group EBITDA loss of A$5.7 million for FY24 improved by 33% (A$2.9 million) from FY23.
- The Glaucoma segment showed a significant trend towards profitability with a A$3.3 million (54%) EBITDA improvement on FY23.
- EBITDA loss of A$0.4 million in H2FY24 was an A$2.1 million (85%) improvement in profitability compared to H1FY24.
- Substantial improvement driven by higher gross margin and return on sales and marketing investment.
- High demand for iTrack Advance™ in the USA as FY25 begins.
- Proposed 30% reimbursement rate increase by CMS, effective from 1 January 2025 in the USA, poised to benefit the business.
- Group sales revenue of A$23.3 million primarily attributable to the glaucoma segment.
- Improved gross margin and returns on investment in new sales representatives and marketing in the USA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pioneer Credit Limited (PNC) ORDINARY FULLY PAID |
Financials |
$79 |
Pioneer ushers in new era for PDP sector disclosure in Aust
|
26 Aug 2024 8:45AM |
$0.485 |
$0.490 |
risen by
1.03%
|
|
| Hearts and Minds Investments Limited (HM1) ORDINARY FULLY PAID |
Financials |
$701 |
Weekly NTA Estimate
|
26 Aug 2024 8:45AM |
$2.700 |
$3.060 |
risen by
13.33%
|
|
| Redcastle Resources Limited (RC1) ORDINARY FULLY PAID |
Materials |
$4 |
Further RC Drilling Planned at Redcastle Projects
|
26 Aug 2024 8:45AM |
$0.015 |
$0.005 |
fallen by
66.67%
|
|
RC1 - Price-sensitive ASX Announcement
Full Release
Key Points
- 7,970m of RC drilling planned at Queen Alexandra and Redcastle Reef
- Drilling to commence in October 2024 subject to rig availability
- Focus on geophysical targets with potential gold-bearing zones
- Activities underway for Mining Proposal submission
- Discussions with contractors and proximal mining operations for custom milling
- Planned extension of current PoWs and submission of new PoWs for future drilling
- Use of advanced geophysics methods anticipated
- Redcastle Project located near Gwalia Gold Mine in a highly prospective area
- Proposed RC drilling includes deep and infill drilling at Redcastle Reef
- Objective to establish a resource and validate geological interpretations
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$33 |
Appendix 4E and Annual Report
|
26 Aug 2024 8:45AM |
$0.230 |
$0.115 |
fallen by
50%
|
|
EYE - Price-sensitive ASX Announcement
Full Release
Key Points
- Nova Eye Medical Limited reported total revenues of $23,325k for the year ended 30 June 2024.
- The company experienced an operating loss before tax of $8,790k.
- The Glaucoma Surgical Devices segment achieved sales of $23,157k, up from $16,661k in the previous year.
- EBITDA loss for Glaucoma Surgical Devices decreased from $6,284k in 2023 to $2,959k in 2024.
- AlphaRET segment focuses on the commercialisation of the 2RT® laser for treating retinal disease.
- The company completed a placement and entitlement offer, raising $7,430k.
- No dividends were paid for the year ended 30 June 2024.
- Current assets as of 30 June 2024 totaled $14,749k, with current liabilities at $5,683k.
- The company is not subject to significant environmental regulations but recognizes the importance of climate change.
- Significant business risks include foreign exchange volatility, supply chain disruptions, and regulatory compliance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Argo Global Listed Infrastructure Limited (ALI) ORDINARY FULLY PAID |
Financials |
$420 |
Media Release - Result for year ended 30 June 2024
|
26 Aug 2024 8:44AM |
$2.200 |
$2.360 |
risen by
7.27%
|
|
ALI - Price-sensitive ASX Announcement
Full Release
Key Points
- Argo Global Listed Infrastructure Limited announced a full-year profit of $12.8 million.
- The company declared a record high fully franked final dividend of 5.0 cents per share.
- Full year dividends increased to 9.0 cents per share, representing a grossed-up yield of 5.6%.
- The final dividend will be paid on 27 September 2024.
- The company's investment portfolio delivered a total return of +4.8% for the year, outperforming the infrastructure benchmark index.
- Persistent high inflation benefited the company due to inflation-linked pricing mechanisms.
- The company’s global portfolio of infrastructure stocks generated an income of $14.9 million, a 3.8% increase from the previous year.
- Global infrastructure stocks showed strong performance, rising +8.8% in July 2024.
- Argo Infrastructure remains well-positioned to benefit from trends like energy transition, manufacturing reshoring, and urbanization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Havilah Resources Limited (HAV) ORDINARY FULLY PAID |
Materials |
$61 |
Non-renounceable Entitlement Offer
|
26 Aug 2024 8:43AM |
$0.175 |
$0.180 |
risen by
2.86%
|
|
HAV - Price-sensitive ASX Announcement
Full Release
Key Points
- 1 for 14 non-renounceable, pro-rata entitlement offer of new Havilah ordinary shares (New Shares) at an offer price of $0.18 per New Share to raise up to approximately $4.07 million.
- Funds to be used primarily for exploration and resource delineation drilling on several high conviction copper-gold-strategic metals prospects in the vicinity of Kalkaroo and Mutooroo.
- Opportunity for Eligible Shareholders to maintain or increase their exposure to Havilah’s high leverage to copper, gold and critical minerals in a projected positive commodities cycle for these metals.
- The indicative timetable for the Entitlement Offer includes multiple key dates, such as the opening of the offer on 3 September 2024 and the closing on 16 September 2024.
- The Entitlement Offer is not underwritten.
- Eligible Shareholders can also apply for Additional New Shares that are not subscribed for under the Entitlement Offer at the same offer price of $0.18 per Additional New Share.
- Shares traded on an ‘ex’ Entitlement basis from 28 August 2024 and the Record Date for the offer is 29 August 2024.
- The Entitlement Offer Booklet will be available to Eligible Shareholders in accordance with the timetable.
- The funds raised aim to explore and delineate copper-gold-strategic metals resources near existing deposits at Kalkaroo and Mutooroo.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biome Australia Limited (BIO) ORDINARY FULLY PAID |
Consumer Staple |
$95 |
Financial Year 2024 Key Results
|
26 Aug 2024 8:43AM |
$0.550 |
$0.435 |
fallen by
20.91%
|
|
BIO - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive EBITDA of $287k for H2 FY24
- Positive cash flow in Q2, Q3, and Q4
- Total sales revenue of $13.01 million, up 80%
- Q4 sales revenue of $3.8 million, up 88% YoY
- International sales reached $894k, up 95%
- Gross profit of $7.91 million with gross margin over 60%
- Same-store sales in Australian pharmacies grew 75%
- Cash balance of $2.87 million as of June 30, 2024
- Secured high-value probiotic intellectual property
- Activated Probiotics brand continues to lead in growth
- Plans to reinvest cash reserves for ongoing growth
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Evolution Mining Limited (EVN) ORDINARY FULLY PAID |
Materials |
$18,983 |
Change of Director's Interest Notice - J Klein
|
26 Aug 2024 8:43AM |
$4.330 |
$9.480 |
risen by
118.94%
|
|
| Perpetual Equity Investment Company Limited (PIC) ORDINARY FULLY PAID |
Financials |
$456 |
Appendix 4G
|
26 Aug 2024 8:43AM |
$1.220 |
$1.190 |
fallen by
2.46%
|
|
| Perpetual Equity Investment Company Limited (PIC) ORDINARY FULLY PAID |
Financials |
$456 |
2024 Corporate Governance Statement
|
26 Aug 2024 8:43AM |
$1.220 |
$1.190 |
fallen by
2.46%
|
|
| Close the Loop Ltd (CLG) ORDINARY FULLY PAID |
Industrials |
$40 |
Annual Report to shareholders
|
26 Aug 2024 8:42AM |
$0.315 |
$0.075 |
fallen by
76.19%
|
|
CLG - Price-sensitive ASX Announcement
Full Release
Key Points
- Close the Loop Limited completed the acquisition of ISP Tek Services and Captive Trade Corp on 28 April 2023.
- Revenue increased by 57% to $212,962,000 for the year ending 30 June 2024.
- Net profit attributable to members was $11,166,000, an increase of 8.8%.
- No dividends were paid or proposed for the year.
- The company is well-positioned within the circular economy with operations across Australia, Europe, South Africa, and the USA.
- The merger with O F Pack Group and listing on ASX allows end-to-end solutions across packaging and consumables.
- Future cash flows projected for 2025 to 2029 with a long-term growth rate of 2.5%.
- The company managed capital with a net debt to adjusted equity ratio of 0.30 times as of 30 June 2024.
- Goodwill from acquisitions tested at a CGU level with no impairment necessary.
- The financial position as of 30 June 2024 shows cash and cash equivalents of $40,644,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metals X Limited (MLX) ORDINARY FULLY PAID |
Materials |
$448 |
Update - Notification of buy-back - MLX
|
26 Aug 2024 8:42AM |
$0.400 |
$0.505 |
risen by
26.25%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
